|
Site outline: |
|
This level:
|
|
Subpages: |
|
|
|
Possibilities: Just as IPT has evolved in the past, it will continue to evolve into the future. Based on past and current trends, here are speculations about things we might see in the IPT methods of the future: 1. New forms of insulin. Insulin has one big limitation, in the eyes of the pharmaceutical industry: It is an old drug, now a commodity and no longer proprietary. As IPT opens up a huge new market for insulin, we may see new forms of insulin that are still faster acting, and easier to deliver to the body. 2. New delivery methods for insulin. Another limitation of insulin is that it is a large molecule that is best delivered intravenously. We may see new insulin delivery systems become more common: oral, transcutaneous, intranasal, inhaler, etc. The inhaler technology of Inhale Therapeutic Systems, Inc. may be the first new insulin delivery system to reach the market.
3. New drugs and combinations. IPT appears to have the ability to turn regular drugs into super drugs, to turn devastatingly toxic drugs into benign and effective drugs. And these are standard drugs, designed and discovered without knowing about IPT. Just imagine what wonders we might see when pharmaceutical companies begin to design new drugs specifically to work with the IPT approach. Similarly, the vast biomedical research community, and all the independent doctors working with patients, are likely to discover new and proprietary combinations of new and existing drugs that work especially well for IPT. There are thousands of potential ingredients out there today, and billions of possible recipes to explore. Oral medications could come in a mixture with oral insulin, making possible, along with oral glucose, a completely oral IPT protocol. Intravenous medications could come in a mixture with glucose, as in the 1939 patent of Dr. Perez Garcia 1. These new combinations could add new patent life to old drugs. Prepare for a pharmaceutical bonanza... 4. New packaging for medications & supplies. Because IPT generally uses a smaller dose of standard drugs, we are likely to see some medications become packaged in smaller portions more appropriate to this procedure. We may also see a stronger emphasis on packaging drugs for intravenous administration, rather than oral or intramuscular, since this provides better control in IPT. IPT supplies and ingredients could come packaged in kits for the convenience of doctors. 5. New devices for administering and monitoring IPT. In Mexico and Canada, depth of hypoglycemia in IPT has usually been determined through observation of symptoms by the doctor. It could be that in the US, technological monitoring of blood sugar during IPT may become standard practice. This could be by standard glucose test strip analysis that uses a drop of blood. Or it could be by any one of the different noninvasive glucose monitors now under development. The equipment needed for IPT today is pretty basic, and usually available to all doctors everywhere. But we may see new kinds of IV bags and drip systems which are optimized for IPT. We may also see automated IPT systems evolve in high-tech countries. Much as computers in automobiles now control and monitor every aspect of fuel injection, air flow, and engine control, computers could also calculate and inject insulin, monitor blood glucose and patient symptoms, inject drugs, and inject glucose. All in a biomedical choreography that is responsive, in the moment, to the patient's changing condition and needs. 6. Gene chips for IPT. New gene sensors could help determine a patient's sensitivity to insulin and the medications to be given with it, and could help determine the appropriate dose. Gene chips will probably prove very valuable in research to track the biochemical processes in IPT. 7. IPT diet for diabetics. It has been generally observed that IPT does not work very well for diabetic patients. Barry Sears PhD suggested to me that his "Zone" diet may help to normalize insulin receptors and metabolism in these patients, thereby improving their response to IPT. 8. New diagnostics and monitoring. It was the dream of Drs. Perez Garcia 1 and 2 in the 1950s and 1960s to develop a simple and inexpensive diagnostic system that could detect cancer and other diseases, even in subclinical stages, and that could then monitor improvement as IPT treatments progress. Today such lab tests as the PSA assay serve a similar purpose. Perhaps after a little research, someone will find scientific support for the Oncodiagnosticator system the Drs. Donato developed, and will bring it up to date with the latest electronic and optical technology. 9. Developing Regions IPT protocol. I hope to see, in the very near future, the development of an IPT protocol that is adapted to the cost, manpower, and facilities constraints found in developing countries. Experimenting with intramuscular insulin administration and oral glucose and medications might help. Eventually, a completely oral IPT protocol would be ideal. Any way to reduce the need for syringes and needles would help. Even using butterfly needles would save on the cost of intravenous drip equipment. I especially look forward to seeing clinical research in the field, where IPT can be tried for treating the many serious diseases that such a large portion of humanity suffer from each day. I think we can save many lives very quickly. 10. New diseases treated by IPT. It seems like half the diseases known to us either have been successfully treated by IPT, or most likely could be, based on projections from known applications. And this is from the efforts of just five doctors over some 70 years. But that is not the end. More and more doctors and researchers will begin to explore this fertile space with new knowledge of the new tools of IPT. The known applications and the possible applications will be tested and proven, and new applications will be found. 11. ...and many more innovations, some of which are as yet unimagined, and some of which are confidential and proprietary at this time. |
